These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 16400314)
41. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973 [No Abstract] [Full Text] [Related]
42. Lessons from the clinic: a case of natalizumab-associated PML. Clifford DB Neurology; 2011 Feb; 76(6):574. PubMed ID: 21300972 [No Abstract] [Full Text] [Related]
43. Reply to "'Thinking without thinking' about natalizumab and PML". Houff S; Berger JR J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798 [No Abstract] [Full Text] [Related]
49. PML: The Dark Side of Immunotherapy in Multiple Sclerosis. Warnke C; Olsson T; Hartung HP Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099 [TBL] [Abstract][Full Text] [Related]
50. Comments on "first-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis". Zhang H; Pan W; Ji W Neurol Sci; 2014 Jun; 35(6):959. PubMed ID: 24554420 [No Abstract] [Full Text] [Related]
51. Therapeutic developments in MS: report from the 57th Annual Meeting of the American Academy of Neurology (AAN), 9-15 April 2004, Miami, Florida, USA. Clanet M Int MS J; 2005 Aug; 12(2):69-70. PubMed ID: 16417817 [TBL] [Abstract][Full Text] [Related]
52. The trials and tribulations of Tysabri. Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299 [No Abstract] [Full Text] [Related]
54. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217 [TBL] [Abstract][Full Text] [Related]
58. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective. Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298 [TBL] [Abstract][Full Text] [Related]
59. Demyelination as a complication of new immunomodulatory treatments. Lysandropoulos AP; Du Pasquier RA Curr Opin Neurol; 2010 Jun; 23(3):226-33. PubMed ID: 20442571 [TBL] [Abstract][Full Text] [Related]